<DOC>
	<DOCNO>NCT00537602</DOCNO>
	<brief_summary>Cystic fibrosis genetic disease cause mutation cystic fibrosis transmembrane conductance regulator ( CFTR ) . The purpose study investigate effect miglustat CFTR function cystic fibrosis patient .</brief_summary>
	<brief_title>Miglustat / OGT 918 Treatment Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Aged 12 year old Male female Nonpregnant woman remain nonpregnant 3 month end study : woman surgically sterile , menopause ( menstruation least one year ) childbearing potential use reliable method contraception . Reliable method contraception female patient include follow : Barrier type device ( e.g. , female condom , diaphragm contraceptive sponge ) use ONLY combination spermicide Intrauterine device Oral contraceptive agent DepoProvera™ ( medroxyprogesterone acetate ) Levonorgestrel implant Abstention , rhythm method contraception partner alone NOT reliable method contraception . For child , reliable method contraception must consider , appropriate . Accepting duration study 3 month thereafter use condom procreate child ( male ) Cystic fibrosis patient homozygous ΔF508 mutation confirm genetic test Signed informed consent prior studymandated procedure Any condition prohibit correct measurement NPD upper respiratory tract infection Acute upper respiratory tract pulmonary exacerbation require antibiotic intervention within 2 week screen Severe renal impairment ( creatinine clearance &lt; 30 ml/min per Cockroft Gault ) Female patient undergo pregnancy test prior enrollment study History significant lactose intolerance History neuropathy History cataract know increased risk cataract formation Presence clinically significant diarrhea ( &gt; 3 liquid stolls per day &gt; 7 day ) without definable cause within 1 month prior screen Any known factor disease might interfere treatment compliance , study conduct interruption result drug alcohol dependence psychiatric disease FEVI &lt; 25 % predict normal Oxygen saturation rest &lt; 88 % Active passive smoking measure use Smokelyzer® Hypersensitivity miglustat excipients Planned treatment treatment another investigational drug therapy ( e.g. , gene therapy ) within 1 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>miglustat</keyword>
	<keyword>Zavesca</keyword>
	<keyword>Actelion</keyword>
	<keyword>nasal potential difference</keyword>
	<keyword>transmembrane conductance regulator ( CFTR )</keyword>
</DOC>